Literature DB >> 25987051

Value of Combined Detection of Serum CEA, CA72-4, CA19-9 and TSGF in the Diagnosis of Gastric Cancer.

Li-Kui Yin1, Xue-Qing Sun, Dong-Zhen Mou.   

Abstract

BACKGROUND: To explore whether combined detection of serum tumor markers (CEA, CA72-4, CA19-9 and TSGF) improve the sensitivity and accuracy in the diagnosis of gastric cancer (GC).
MATERIALS AND METHODS: An automatic chemiluminescence immune analyzer with matched kits were used to determine the levels of serum CEA, CA72-4, CA19-9 and TSGF in 45 patients with gastric cancer (GC group), 40 patients with gastric benign diseases (GBD group) hospitalized in the same period and 30 healthy people undergoing a physical examination. The values of those 4 tumor markers in the diagnosis of gastric cancer was analyzed.
RESULTS: The levels of serum CEA, CA72-4, CA19-9 and TSGF of the GC group were higher than those of the GBD group and healthy examined people and the differences were significant (P<0.001). The area under receiver operating characteristic (ROC) curves for single detection of CEA, CA72-4, CA19-9 and TSGF in the diagnosis of GC was 0.833, 0.805, 0.810 and 0.839, respectively. The optimal cutoff values for these 4 indices were 2.36 ng/mL, 3.06 U/mL, 5.72 U/ mL and 60.7 U/mL, respectively. With combined detection of tumor markers, the diagnostic power of those 4 indices was best, with an area under the ROC curve of 0.913 (95%CI 0.866~0.985), a sensitivity of 88.9% and a diagnostic accuracy of 90.4%.
CONCLUSIONS: Combined detection of serum CEA, CA72-4, CA19-9 and TSGF increases the sensitivity and accuracy in diagnosis of GC, so it can be regarded as the important means for early diagnosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25987051     DOI: 10.7314/apjcp.2015.16.9.3867

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  15 in total

1.  Use of serum and peritoneal CEA and CA19-9 in prediction of peritoneal dissemination and survival of gastric adenocarcinoma patients: are they prognostic factors?

Authors:  M Hasbahceci; F U Malya; E Kunduz; M Guzel; N Unver; A Akcakaya
Journal:  Ann R Coll Surg Engl       Date:  2018-03-15       Impact factor: 1.891

Review 2.  [Advances in serum biomarkers for early diagnosis of gastric cancer].

Authors:  Yunzhu Zhang; Chunpeng Zhu; Xinliang Lu
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2019-05-25

3.  CdSe/ZnS Quantum Dot-Labeled Lateral Flow Strips for Rapid and Quantitative Detection of Gastric Cancer Carbohydrate Antigen 72-4.

Authors:  Xinyu Yan; Kan Wang; Wenting Lu; Weijian Qin; Daxiang Cui; Jinghua He
Journal:  Nanoscale Res Lett       Date:  2016-03-11       Impact factor: 4.703

4.  A novel classifier based on three preoperative tumor markers predicting the cancer-specific survival of gastric cancer (CEA, CA19-9 and CA72-4).

Authors:  Jing Guo; Shangxiang Chen; Shun Li; Xiaowei Sun; Wei Li; Zhiwei Zhou; Yingbo Chen; Dazhi Xu
Journal:  Oncotarget       Date:  2017-12-14

5.  Circulating Exosomal Gastric Cancer-Associated Long Noncoding RNA1 as a Biomarker for Early Detection and Monitoring Progression of Gastric Cancer: A Multiphase Study.

Authors:  Xin Guo; Xiaohui Lv; Yi Ru; Fuxing Zhou; Ning Wang; Hongqing Xi; Kecheng Zhang; Jiyang Li; Rongyan Chang; Tianyu Xie; Xinxin Wang; Baohai Li; Yong Chen; Yanling Yang; Lubin Chen; Lin Chen
Journal:  JAMA Surg       Date:  2020-07-01       Impact factor: 14.766

6.  High serum MMP-14 predicts worse survival in gastric cancer.

Authors:  Aaro Kasurinen; Taina Tervahartiala; Alli Laitinen; Arto Kokkola; Timo Sorsa; Camilla Böckelman; Caj Haglund
Journal:  PLoS One       Date:  2018-12-07       Impact factor: 3.240

Review 7.  The role and diagnostic potential of gastrokine 1 in gastric cancer.

Authors:  Olga M Koper-Lenkiewicz; Joanna Kamińska; Beata Gawrońska; Joanna Matowicka-Karna
Journal:  Cancer Manag Res       Date:  2019-03-01       Impact factor: 3.989

8.  Efficacy and safety of cord blood-derived dendritic cells plus cytokine-induced killer cells combined with chemotherapy in the treatment of patients with advanced gastric cancer: a randomized Phase II study.

Authors:  Ying Mu; Wei-Hua Wang; Jia-Ping Xie; Ying-Xin Zhang; Ya-Pei Yang; Chang-Hui Zhou
Journal:  Onco Targets Ther       Date:  2016-07-25       Impact factor: 4.147

9.  Plasma activity of Thioredoxin Reductase as a Novel Biomarker in Gastric Cancer.

Authors:  Wei Peng; Zhaofei Zhou; Yuejiao Zhong; Yan Sun; Yajing Wang; Zili Zhu; Wenxuan Jiao; Man Bai; Jing Sun; Jianwei Lu; Hanwei Yin
Journal:  Sci Rep       Date:  2019-12-13       Impact factor: 4.379

Review 10.  Significant function and research progress of biomarkers in gastric cancer.

Authors:  Dong Mei Ye; Gaosheng Xu; Wei Ma; Yuxuan Li; Weiru Luo; Yiyang Xiao; Yong Liu; Zhiwei Zhang
Journal:  Oncol Lett       Date:  2019-11-11       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.